Thumbnail

High costs may be keeping working-age heart patients from seeking care

When working-age adults develop cardiovascular disease, it often ends up eating up a significant amount of their income. Are insurance companies doing enough to help these patients? 

heart patient

A ‘disquieting plateau’: Healthcare costs are up, but survival among heart patients stays the same

The cardiovascular mortality rate in the United States decreased dramatically from 2000 to 2011. Since then, however, it has remained relatively unchanged.

Trump White House RFK Make America Health Again

Public trust in US health agencies falls under Trump—confidence in AHA still quite high

The public has more confidence in the American Heart Association than it does in the FDA, CMS or any other federal health agencies. 

Angiography demonstrates a high-grade, modestly angulated stenosis (arrow) in the proximal segment of a large diagonal branch (A). Predilation performed with difficulty, and the GEC could not be advanced beyond stenosis even with “inch worming” techniques. (B). Advancement of the CrossFAST (C) beyond the proximal stent edge stenosis (a.), the position of the distal end of the outer catheter (b.), and the microcatheter tip (c.) are indicated.

Next-generation guide extension catheter delivers value during complex PCI

The CrossFAST system was successfully used to deploy multiple stents after other devices fell short. 

Semaglutide, the GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic, is associated with significant health benefits for patients with type 2 diabetes and peripheral artery disease (PAD), according to a late-breaking clinical trial presented at ACC.25, the annual meeting of the American College of Cardiology (ACC).

American College of Cardiology announces late-breaking clinical trials for ACC.26

The American College of Cardiology's 2026 annual meeting will include an all-time record of 60 late-breaking clinical studies.

robot reviewing heart data

Cardiologists develop new AI screening tool for structural heart disease

Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.

Thumbnail

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.

The Relief System from Relief Cardiovascular Inc. is a first of its kind device. It incorporates a valve and sensor implant that uses AI to intelligently modulate venous pressure using hemodynamic data. The system actively adjusts flow in the inferior vena cava (IVC), which lowers venous pressure to drive durable decongestion in heart failure.

New AI-enabled heart failure implant shows early potential

The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.